Table 1.

Patient characteristics (n = 150)




No.

%
Sex, M/F   75/75   50/50  
FAB   
    M0   6   4  
    1   19   13  
    2   46   31  
    3   8   5  
    4   41   27  
    5   20   13  
    6   2   1  
    7   7   5  
    No data   1   1  
Cytogenetics  85   57  
    Normal   17   20  
    t(15;17)   6   7  
    t(8;21)   17   20  
    Abnormal 16*  13   15  
    Abnormal 11  12   14  
    -7/7q-   3   4  
    +8   3   4  
    Other   14   16  
Induction chemotherapy   
    Intensive timing   94   63  
    Standard timing   52   35  
    Intensive/standard timing   4   3  
Splenomegaly at diagnosis   
    None   95   63  
    Enlarged   55   37  
Hepatomegaly at diagnosis   
    None   95   63  
    Enlarged   55   37  
Donor   
    Parent   11   7  
    Sibling   138   92  
    Unknown
 
1
 
1
 



No.

%
Sex, M/F   75/75   50/50  
FAB   
    M0   6   4  
    1   19   13  
    2   46   31  
    3   8   5  
    4   41   27  
    5   20   13  
    6   2   1  
    7   7   5  
    No data   1   1  
Cytogenetics  85   57  
    Normal   17   20  
    t(15;17)   6   7  
    t(8;21)   17   20  
    Abnormal 16*  13   15  
    Abnormal 11  12   14  
    -7/7q-   3   4  
    +8   3   4  
    Other   14   16  
Induction chemotherapy   
    Intensive timing   94   63  
    Standard timing   52   35  
    Intensive/standard timing   4   3  
Splenomegaly at diagnosis   
    None   95   63  
    Enlarged   55   37  
Hepatomegaly at diagnosis   
    None   95   63  
    Enlarged   55   37  
Donor   
    Parent   11   7  
    Sibling   138   92  
    Unknown
 
1
 
1
 

FAB indicates French-American-British classification.

*

Thirteen cases had inversion 16, 1 patient had a balanced translocation, and 1 had a partial deletion of chromosome 16.

All had abnormalities of 11q23.

or Create an Account

Close Modal
Close Modal